Dr. Arvind N. Dasari, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 140
Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license P0718 (first issued 2011; active) -
Internal Medicine Physician
PA license MT186584
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 140
- Services billed
- 318
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 247 | 114 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Everolimus | 42 |
| Ondansetron Hcl Other prescribers in Houston, TX | 30 |
| Prochlorperazine Maleate Other prescribers in Houston, TX | 26 |
| Loperamide (loperamide hcl) Other prescribers in Houston, TX | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 14 payments worth $13,313 in total to this clinician.
| Genzyme Corporation | $3,855 |
|---|---|
| Taiho Oncology, Inc. | $3,284 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,633 |
| Exelixis Inc. | $2,544 |
| Shionogi Inc | $816 |
| Tersera Therapeutics LLC | $112 |
| Pulmonx Corporation | $40.92 |
| Incyte Corporation | $28.45 |
| Consulting Fee | $7,655 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,633 |
| Honoraria | $2,400 |
| Food and Beverage | $625 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jan 22, 2025 | Consulting Fee | $3,740 |
| Taiho Oncology, Inc. Jul 1, 2025 | Consulting Fee LONSURF · Oncology | $3,120 |
| Exelixis Inc. Jul 1, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,400 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · Oncology · in-kind | $2,268 |
| Shionogi Inc Feb 5, 2025 | Consulting Fee | $680 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 1, 2025 | Compensation for services other than consulting (speaking, faculty) FRUZAQLA · Oncology · in-kind | $365 |
| Genzyme Corporation Jan 22, 2025 | Consulting Fee | $115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $1,022,868 in research payments for these studies, mostly to the institutions running them.
- A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Novartis Pharmaceuticals Corporation - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05477576 - A Phase II Study of Lenvatinib in Combination with Everolimus in Patients with Advanced Carcinoid Tumors
Eisai Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.